ORIC – oric pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Oric Pharmaceuticals (NASDAQ:ORIC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
Form 4 Oric Pharmaceuticals, For: Dec 15 Filed by: Multani Pratik S
Form 4 Oric Pharmaceuticals, For: Dec 15 Filed by: Piscitelli Dominic
Form 4 Oric Pharmaceuticals, For: Dec 15 Filed by: Chacko Jacob
Form 144 Oric Pharmaceuticals, Filed by: Piscitelli Dominic
Form 144 Oric Pharmaceuticals, Filed by: Multani Pratik S
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.